Valneva SE (VALN) company profile
Close on Nov 17, 2026Market cap $482.87MP/E –Yield –
About Valneva
Biological Products, (No Diagnostic Substances), SIC 2836
Valneva SE is a specialty vaccine company that discovers, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with significant unmet medical needs. The company's commercialized product portfolio features travel vaccines, including IXIARO for the prevention of Japanese encephalitis, DUKORAL for cholera and traveler's diarrhea caused by LT-ETEC, and IXCHIQ for chikungunya. Valneva serves travelers, military personnel, and global populations vulnerable to endemic infectious threats. Additionally, it advances late-stage clinical candidates, such as a Lyme disease vaccine developed in partnership with Pfizer and a tetravalent Shigella vaccine candidate.
The company operates manufacturing and research facilities across Europe, including production sites in Scotland and Sweden. It conducts business and maintains wholly owned operating subsidiaries in France, Austria, Scotland, Sweden, England and Wales, Canada, and the United States. Valneva maintains its registered corporate headquarters in Lyon, France.
Summary of the business section of Valneva's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Valneva SE
- Founded
- 1999
- Headquarters
- Saint-Herblain, I0
- Address
- 6, Rue Alain Bombard 44800
- Phone
- 33 2 28 07 37 10
- Website
- valneva.com
- Employees
- 140, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- I0
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Associes, Paris, France
Stock & identifiers
- Ticker
- VALN
- Exchange
- Nasdaq
- IPO date
- May 7, 2021
- Shares outstanding
- 174M, Dec 31, 2025
- Filer category
- Accelerated filer
- SEC CIK
- 1836564
- CUSIP
- 92025Y103
- ISIN
- US92025Y1038
- FIGI
- BBG00ZZPBH08
- Share class FIGI
- BBG00ZZPBHX2
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
Valneva's leadership is listed in its proxy statement (Form DEF 14A).
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 7, 2021
- Offer price
- $26.41
- Exchange
- Nasdaq
- First trading day
- May 5, 2021
- First-day close
- $26.41-0.0%
- Lock-up ends (est.)
- Nov 1, 2021
“Our ADSs have been approved for listing on the Nasdaq Global Select Market under the symbol “VALN.” Our ordinary shares are listed on Euronext Paris under the symbol “VLA.” The initial public offering price is $26.411 per ADS in the U.S.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“The site supports multi‑product manufacturing and serves as our viral vaccine center of excellence, employing approximately 140 staff.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 7, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| May 3, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?